Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin + Anti-PD-1 + S-1 in Advanced Pancreatic Cancer
NCT07892573Recruiting
- Sponsor
- Ningbo Medical Centre Lihuili Hospital
- Start
- Oct 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of becotatug vedotin in pancreatic cancer (PC), sponsored by Ningbo Medical Centre Lihuili Hospital. Primary endpoint: Objective Response Rate. Started Oct 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07892573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07892573.